MARKETS / NASDAQ / ARAY
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · MID CAP

Accuray Incorporated ARAY

16 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$458.5M
▲ 2.7% vs FY2023
EPS · FY24
$-0.02
Dividend / sh · FY24
Payout · FY24
ROE · FY24
-2.5%
Net margin · FY24
-0.3%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 458.5M
Revenue, FY2024 · full 16-year series below
Revenue Net income
0.20.40.60.5-0.0200920122015201820212024
0.20.40.60.5-0.02015201820212024

The company lost 0 cents on every revenue dollar this year.

Per share
USD -0.02
Diluted EPS, FY2024
EPS
0.40.81.2-0.02200920122015201820212024
0.40.81.2-0.022015201820212024

The company pays no cash dividend.

Profitability
-2.5%
Return on equity, FY2024
ROE
2468-2.5%200920122015201820212024
2468-2.5%2015201820212024
Operating margin1.7%
Net margin-0.3%
Return on assets-0.3%

Each USD of equity lost 3 cents this year.

Returned to shareholders
returned in FY2024 · dividends + net buybacks
Dividends paid
Net buybacks
Share of profit
Consecutive raises

Growth
+3.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+2.2%
+3.7%
+1.9%
+5.0%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
0.11B
Shares outstanding, FY2024
0.070.11200920122015201820212024
0.080.112015201820212024
Change, 5 years+23.5%
Change, 10 years+41.7%

The share count grew 24% in five years — the same company, cut into more, smaller slices.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 470.2M
total assets, end of FY2024
Total assetsUSD 470.2M
EquityUSD 81.2M
CashUSD 57.4M
Gross debtUSD 136.5M
Net debtUSD 79.1M
Current ratio1.65×

Net debt stands at 97% of equity.

History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.5
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.4
0.3
0.4
0.2
0.2
Operating income $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.0
0.0
EBITDA $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.1
−0.0
−0.0
0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.0
0.0
EPS, diluted $
−0.02
−0.16
−0.10
−0.06
−0.07
0.04
−0.19
−0.28
−0.36
−0.32
−0.51
−0.47
−1.41
−1.02
−0.44
0.05
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−2.5
−31.5
−17.4
−8.8
−9.5
6.7
−33.4
−50.2
−55.7
−37.7
−46.1
−34.5
−75.0
−32.4
−11.3
·
Shares out B
0.11
0.10
0.10
0.09
0.09
0.09
0.09
0.09
0.08
0.08
0.08
0.08
0.07
0.07
0.07
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
62 of 62
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed